continued treatment helps maintain losses Common side effects that may affect treatment adherence include: Nausea and vomiting (usually temporary, improving after several weeks) Diarrhoea or constipation Abdominal discomfort Fatigue Injection site reactions Important safety considerations include: Risk of hypoglycaemia if used with insulin or sulfonylureas [4] Do not stop or reduce insulin rapidly without medical advice (risk of diabetic ketoacidosis) [4] Maintain adequate hydration to prevent acute kidney injury [4] Potential for gallbladder problems (pain, stones) Rare risk of intestinal obstruction Possible worsening of diabetic retinopathy in people with diabetes during rapid improvement in blood glucose For tirzepatide: use additional non-oral contraception for 4 weeks after initiation and each dose escalation Patients should contact their GP if they experience: persistent vomiting preventing fluid intake, severe abdominal pain, signs of gallbladder disease, or unusual thyroid symptoms
Pauling This Pharmacology Consult will focus on GLP-1 receptor agonists that are currently FDA approved for weight loss, including semaglutide (Wegovy, Novo Nordisk) and liraglutide (Saxenda, Novo Nordisk), but other FDA-approved options exist, such as orlistat, naltrexone/bupropion and phentermine/topiramate
The Lewy body is a neuron inclusion body, mainly composed of -synuclein (56)
Yes, like every other weight loss medication, GLP-1 medications also have temporary side effects
During the study period, use of GLP-1 RAs increased by 140.4%, the researchers found
Frequently asked questions How long should I hold GLP-1 drops under my tongue
